Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773865 | 0.86 | PLA2G2A (0.41) | MAPTPLA2G2AALDH1A1LMNAHTT | |
| SCHEMBL1401053 | 0.82 | PLA2G2A (0.36) | PLA2G2AALDH1A1LMNA | |
| SCHEMBL3773863 | 0.82 | PLA2G2A (0.36) | PLA2G2AALDH1A1LMNA | |
| SCHEMBL1401179 | 0.82 | PLA2G2A (0.36) | PLA2G2AALDH1A1LMNA | |
| SCHEMBL3780082 | 0.81 | ABCG2 (0.36) | PLA2G2AALDH1A1LMNA | |
| SCHEMBL3779589 | 0.81 | PLA2G2A (0.36) | PLA2G2A | |
| SCHEMBL5816742 | 0.79 | ALDH1A1 (0.46) | MAPTPLA2G2AALDH1A1LMNAHTT | |
| SCHEMBL4957637 | 0.78 | MAPT (0.44) | CYSLTR1CNR2MAPTL3MBTL1PLA2G2A | |
| SCHEMBL9756946 | 0.76 | CYSLTR2 (0.45) | CYSLTR1CYSLTR2CNR2MAPTL3MBTL1 | |
| SCHEMBL1401054 | 0.73 | PLA2G2A (0.38) | MAPTPLA2G2AALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | SATYANARAYANA CHAVA | 2008-11-06 | — | — | US | claimed |
| US-7858793-B2 | Methyl 2-[(3S)-[3-[2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates | SATYANARAYANA CHAVA | 2010-12-28 | — | — | US | disclosed |
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | SATYANARAYANA CHAVA | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | HTR3C, HTR3B, TPMT | CYSLTR1 3478/4885CYSLTR2 2907/4885CNR2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.